查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575048

顱內治療遞送市場，按治療方法、適應症、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Intracranial Therapeutic Delivery Market, By Therapy, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年顱內治療遞送市場規模為198,032萬美元，2024年至2032年複合年成長率為7.99%。

該領域的創新旨在透過精確靶向、持續釋放和增強藥物的生物利用度來改善患者的治療結果。隨著研究的進展，市場也看到了神經學應用的基因治療和生物製劑的發展。神經系統疾病的日益普及和醫療技術的進步是推動該領域需求的關鍵因素，使其成為現代醫療保健的關鍵領域。

顱內治療遞送市場-市場動態

神經系統疾病盛行率的增加推動了對標靶治療的需求。

神經系統疾病盛行率的增加是顱內治療遞送市場的重要驅動力。隨著人口老化，阿茲海默症、帕金森氏症和多發性硬化症等疾病變得越來越常見，需要先進的治療方案。據 CDC 稱，預計 2020 年美國有六分之一的成年人患有神經系統疾病。

此外，提高意識和早期診斷有助於越來越多的患者尋求專門護理。隨著醫療保健系統努力應對這些挑戰，新型顱內輸送方法的研發投資預計將擴大，為市場成長創造機會。

顱內治療遞送市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 7.99% 左右的複合年成長率成長

根據治療細分，基因治療預計將在 2023 年顯示最大的市場佔有率

根據適應症細分，多發性硬化症是 2023 年的主導類型

按地區分類，北美是 2023 年的主要收入來源

顱內治療遞送市場-細分分析：

全球顱內治療遞送市場根據治療、適應症和區域進行細分。

根據療法，市場分為三類：細胞療法、基因療法和酵素替代療法。基因治療是顱內治療遞送市場中最突出的。這種方法有可能解決神經系統疾病的潛在遺傳原因，提供長期解決方案而不僅僅是緩解症狀。載體技術和 CRISPR 基因編輯的進步正在增強基因療法的功效和安全性，使其對於遺傳性癲癇和神經退化性疾病等疾病越來越可行。對個人化醫療的日益關注進一步推動了對基因治療的需求，因為治療可以根據個別基因譜進行客製化。總體而言，其創新性和變革潛力使基因治療成為市場的領先領域。

根據適應症，市場分為四類：脊髓性肌肉萎縮症（SMA）、多發性硬化症、巴頓氏症和肌肉萎縮側索硬化症。多發性硬化症（MS）是顱內治療遞送市場中最突出的。多發性硬化症影響著全球數百萬人，導致對能夠控制其複雜症狀並減緩疾病進展的創新治療方案的巨大需求。包括單株抗體和口服治療在內的療法的進步正在改善患者的治療效果並推動市場成長。多發性硬化症的盛行率不斷上升，以及對更有效的給藥方法的持續研究，強調了其作為治療開發焦點的重要性。隨著認知和診斷的提高，多發性硬化症相關治療的市場不斷擴大，鞏固了其主導地位。

顱內治療遞送市場 - 地理洞察

北美成為顱內治療遞送市場最大的地區，主要得益於領先的醫療保健公司、先進的研究設施和強大的監管框架的存在。尤其是美國，由於醫療保健支出高、對創新的高度重視以及容易患神經系統疾病的人口老化，佔據了很大的佔有率。此外，有利的報銷政策和完善的臨床試驗基礎設施支持市場成長。

該地區對神經學研究的投資也不斷增加，這促進了新治療方式的發展。雖然歐洲和亞太地區是需求不斷成長的新興市場，但北美成熟的醫療保健生態系統繼續引領步伐，使其成為尋求顱內治療交付創新的現有參與者和新進者的焦點。

顱內治療遞送市場-競爭格局：

顱內治療遞送市場的特徵是老牌企業和新興生技公司之間競爭激烈。美敦力（Medtronic）和艾伯維（AbbVie）等主要公司以其廣泛的產品組合和強大的研發能力佔據主導地位，專注於先進的藥物輸送系統和神經系統疾病的創新療法。此外，史賽克和波士頓科學公司利用其在手術設備領域的強大影響力來提高治療效果。

NeuroRx 和 Zynerba Pharmaceuticals 等新興企業正在引入新穎的治療方式，包括基於大麻素的療法，這使市場格局多樣化。隨著公司尋求加速創新和擴大市場範圍，協作和策略夥伴關係很常見。監管挑戰和臨床驗證的需求仍然是影響競爭策略的關鍵障礙。總體而言，隨著技術的進步和對神經系統疾病的更深入了解推動新產品開發，市場有望成長。

最新進展：

2024 年 9 月，CereVasc 的血管內裝置有潛力成為直接向大腦進行基因治療的新型輸送系統，從而提高神經系統疾病的治療效果。透過利用這種方法，旨在增強標靶治療，同時最大限度地減少與傳統方法相關的侵入性和副作用。

目錄

第1章：顱內治療遞送市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 顱內治療遞送市場片段（依療法）
    • 依適應症分類的顱內治療遞送市場片段
    • 按國家/地區分類的顱內治療遞送市場片段
    • 按地區分類的顱內治療遞送市場片段
  • 競爭洞察

第 3 章：顱內治療遞送主要市場趨勢

  • 顱內治療遞送市場促進因素
    • 市場促進因素的影響分析
  • 顱內治療遞送市場的限制
    • 市場限制影響分析
  • 顱內治療遞送市場機會
  • 顱內治療遞送市場未來趨勢

第 4 章：顱內治療遞送產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：顱內治療遞送市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：顱內治療遞送市場格局

  • 2023 年顱內治療遞送市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：顱內治療遞送市場 - 按治療

  • 概述
    • 按療法分類的細分市場佔有率分析
    • 細胞療法
    • 基因治療
    • 酵素替代療法

第 8 章：顱內治療遞送市場 - 按適應症

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 脊髓性肌肉萎縮症 (SMA)
    • 多發性硬化症
    • 巴頓病
    • 肌萎縮側索硬化症
    • 其他

第 9 章：顱內治療遞送市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美顱內治療傳輸主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按治療）
    • 北美市場規模和預測（按指標）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲顱內治療傳輸主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按治療）
    • 歐洲市場規模與預測（按指標）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區顱內治療傳遞主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按治療）
    • 亞太地區市場規模與預測（依指標）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲顱內治療傳輸主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按療法）
    • 拉丁美洲市場規模與預測（按指標）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲顱內治療傳輸主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模和預測（按治療）
    • 中東和非洲市場規模及預測（依指標）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 10 章：主要供應商分析 - 顱內治療輸送產業

  • 競爭儀表板
  • 公司簡介
    • Medtronic
    • AbbVie
    • Stryker Corporation
    • Baxter International
    • Ipsen SA
    • Johnson & Johnson (Ethicon)
    • NuVasive
    • NeuroRx
    • CureVac AG
    • Boston Scientific
    • Aesculap
    • Zynerba Pharmaceuticals
    • Elekta
    • Intra-Cellular Therapies

第 11 章：360 度分析師視角

第 12 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4050

REPORT HIGHLIGHT

Intracranial Therapeutic Delivery Market size was valued at USD 1,980.32 Million in 2023, expanding at a CAGR of 7.99% from 2024 to 2032.

The intracranial therapeutic delivery market focuses on methods and technologies used to administer treatments directly into the cranial cavity, targeting conditions such as brain tumors, epilepsy, and neurodegenerative disorders. This market encompasses a variety of delivery systems, including implantable devices, infusions, and drug-eluting technologies that optimize therapeutic efficacy and minimize side effects.

Innovations in this field aim to improve patient outcomes through precise targeting, sustained release, and enhanced bioavailability of medications. As research progresses, the market is also seeing developments in gene therapy and biologics for neurological applications. The growing prevalence of neurological disorders and advances in medical technology are key factors driving demand in this sector, making it a critical area of focus in modern healthcare.

Intracranial Therapeutic Delivery Market- Market Dynamics

Increased prevalence of neurological disorders driving demand for targeted therapies.

The increasing prevalence of neurological disorders is a significant driver for the intracranial therapeutic delivery market. As the population ages, conditions such as Alzheimer's, Parkinson's, and multiple sclerosis are becoming more common, necessitating advanced treatment options. According to the CDC, an estimated 1 in 6 adults in the U.S. reported having a neurological condition in 2020. This rising incidence fuels the demand for innovative therapeutic delivery systems that can provide targeted and effective treatments.

Furthermore, greater awareness and early diagnosis contribute to the growing patient pool seeking specialized care. As healthcare systems strive to address these challenges, investments in research and development for novel intracranial delivery methods are expected to expand, creating opportunities for market growth.

Intracranial Therapeutic Delivery Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.99% over the forecast period (2024-2032)

Based on Therapy segmentation, Gene Therapy, was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Multiple Sclerosis was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Intracranial Therapeutic Delivery Market- Segmentation Analysis:

The Global Intracranial Therapeutic Delivery Market is segmented based on Therapy, Indication, and Region.

The market is divided into three categories based on Therapy: Cell-based Therapy, Gene Therapy, and Enzyme Replacement Therapy. Gene Therapy is the most prominent in the intracranial therapeutic delivery market. This approach offers the potential to address the underlying genetic causes of neurological disorders, providing long-term solutions rather than just symptomatic relief. Advances in vector technology and CRISPR gene editing are enhancing the efficacy and safety of gene therapies, making them increasingly viable for conditions like genetic forms of epilepsy and neurodegenerative diseases. The growing focus on personalized medicine further propels the demand for gene therapy, as treatments can be tailored to individual genetic profiles. Overall, its innovative nature and transformative potential position gene therapy as a leading segment in the market.

The market is divided into four categories based on Indication: Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Batten Disease, and Amyotrophic Lateral Sclerosis. Multiple Sclerosis (MS) is the most prominent in the intracranial therapeutic delivery market. MS affects millions globally, leading to significant demand for innovative treatment options that can manage its complex symptoms and slow disease progression. Advances in therapies, including monoclonal antibodies and oral treatments, are enhancing patient outcomes and driving market growth. The increasing prevalence of MS, along with ongoing research into more effective delivery methods, underscores its importance as a focal point for therapeutic development. As awareness and diagnosis improve, the market for MS-related treatments continues to expand, solidifying its position as a dominant segment.

Intracranial Therapeutic Delivery Market- Geographical Insights

North America stands out as the largest region in the intracranial therapeutic delivery market, driven primarily by the presence of leading healthcare companies, advanced research facilities, and a robust regulatory framework. The United States, in particular, accounts for a significant share due to high healthcare expenditure, a strong emphasis on innovation, and an aging population prone to neurological disorders. Additionally, favorable reimbursement policies and a well-established infrastructure for clinical trials support market growth.

The region is also witnessing increased investments in neurological research, which fosters the development of new therapeutic modalities. While Europe and Asia-Pacific are emerging markets with growing demand, North America's established healthcare ecosystem continues to set the pace, making it a focal point for both existing players and new entrants looking to innovate in intracranial therapeutic delivery.

Intracranial Therapeutic Delivery Market- Competitive Landscape:

The intracranial therapeutic delivery market is characterized by intense competition among established players and emerging biotech firms. Key companies like Medtronic and AbbVie dominate with their extensive product portfolios and robust R&D capabilities, focusing on advanced drug delivery systems and innovative therapies for neurological conditions. Additionally, Stryker and Boston Scientific leverage their strong presence in surgical devices to enhance therapeutic outcomes.

Emerging players, such as NeuroRx and Zynerba Pharmaceuticals, are introducing novel treatment modalities, including cannabinoid-based therapies, which diversify the market landscape. Collaboration and strategic partnerships are common as companies seek to accelerate innovation and expand their market reach. Regulatory challenges and the need for clinical validation remain critical hurdles, influencing competitive strategies. Overall, the market is poised for growth as advancements in technology and a deeper understanding of neurological diseases drive new product development.

Recent Developments:

In September 2024, CereVasc's endovascular device has the potential to serve as a novel delivery system for gene therapy directly to the brain, improving treatment efficacy for neurological conditions. By utilizing this approach, aims to enhance targeted therapy while minimizing invasiveness and side effects associated with traditional methods.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Medtronic
  • AbbVie
  • Stryker Corporation
  • Baxter International
  • Ipsen S.A.
  • Johnson & Johnson (Ethicon)
  • NuVasive
  • NeuroRx
  • CureVac AG
  • Boston Scientific
  • Aesculap
  • Zynerba Pharmaceuticals
  • Elekta
  • Intra-Cellular Therapies

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Cell-based Therapy
  • Gene Therapy
  • Enzyme Replacement Therapy

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Spinal Muscular Atrophy (SMA)
  • Multiple Sclerosis
  • Batten Disease
  • Amyotrophic Lateral Sclerosis
  • Others

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Intracranial Therapeutic Delivery Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Intracranial Therapeutic Delivery Market Snippet by Therapy
    • 2.1.2. Intracranial Therapeutic Delivery Market Snippet by Indication
    • 2.1.3. Intracranial Therapeutic Delivery Market Snippet by Country
    • 2.1.4. Intracranial Therapeutic Delivery Market Snippet by Region
  • 2.2. Competitive Insights

3. Intracranial Therapeutic Delivery Key Market Trends

  • 3.1. Intracranial Therapeutic Delivery Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Intracranial Therapeutic Delivery Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Intracranial Therapeutic Delivery Market Opportunities
  • 3.4. Intracranial Therapeutic Delivery Market Future Trends

4. Intracranial Therapeutic Delivery Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Intracranial Therapeutic Delivery Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Intracranial Therapeutic Delivery Market Landscape

  • 6.1. Intracranial Therapeutic Delivery Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Intracranial Therapeutic Delivery Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2023 & 2032 (%)
    • 7.1.2. Cell-based Therapy
    • 7.1.3. Gene Therapy
    • 7.1.4. Enzyme Replacement Therapy

8. Intracranial Therapeutic Delivery Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Spinal Muscular Atrophy (SMA)
    • 8.1.3. Multiple Sclerosis
    • 8.1.4. Batten Disease
    • 8.1.5. Amyotrophic Lateral Sclerosis
    • 8.1.6. Others

9. Intracranial Therapeutic Delivery Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Intracranial Therapeutic Delivery Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Intracranial Therapeutic Delivery Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Intracranial Therapeutic Delivery Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Intracranial Therapeutic Delivery Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Intracranial Therapeutic Delivery Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Intracranial Therapeutic Delivery Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Medtronic
    • 10.2.2. AbbVie
    • 10.2.3. Stryker Corporation
    • 10.2.4. Baxter International
    • 10.2.5. Ipsen S.A.
    • 10.2.6. Johnson & Johnson (Ethicon)
    • 10.2.7. NuVasive
    • 10.2.8. NeuroRx
    • 10.2.9. CureVac AG
    • 10.2.10. Boston Scientific
    • 10.2.11. Aesculap
    • 10.2.12. Zynerba Pharmaceuticals
    • 10.2.13. Elekta
    • 10.2.14. Intra-Cellular Therapies

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us